EVALI: What the 2019 Vaping Lung Injury Outbreak Actually Was

In the summer and fall of 2019, hundreds of vapers began arriving at emergency departments with severe lung injuries: shortness of breath, coughing, chest pain, and in some cases respiratory failure. The condition was named EVALI (e-cigarette, or vaping, product use-associated lung injury), and within months it had been reported in over 2,800 people across the US, with 68 deaths [3]. It was frightening, and the fear was reasonable. The reporting around it, however, was often less precise than the investigation that followed.

If you were vaping in 2019, you probably remember the headlines. They mostly said “vaping causes lung injury” without distinguishing between products, and the result was confusion that persists years later. The actual story is narrower and more specific, and understanding it matters for anyone trying to make sense of the risks of nicotine vaping.

What the investigation found

The CDC and FDA investigation identified the cause: vitamin E acetate, a lipid compound used as a thickening agent in illicit THC vaping cartridges [1]. Vitamin E acetate is chemically similar to the vitamin E found in supplements and skin creams. Ingested or applied to skin, it is harmless. But when inhaled as an aerosol, it coats the alveoli, the tiny air sacs where oxygen exchange happens, and disrupts their function. The lipid layer prevents the normal gas exchange that keeps you alive. The result is a chemical pneumonia that can progress to respiratory failure.

In the key study, bronchoalveolar lavage (BAL) fluid from 51 EVALI patients was tested for vitamin E acetate. It was found in 94% of them. It was found in 0% of the healthy comparison group [1]. This is as strong as epidemiological evidence gets for an environmental cause. The association was specific, consistent, and biologically plausible: the compound was in the lungs of nearly every patient and in none of the controls.

The clinical presentation was also specific. EVALI patients typically developed symptoms over days to weeks: shortness of breath, coughing, chest pain, nausea, abdominal pain, and fever [2]. Many were initially misdiagnosed with pneumonia or influenza because the respiratory symptoms overlapped significantly with common respiratory infections, and because in 2019, most emergency physicians had not yet encountered vaping-related lung injury as a diagnostic category. The lung imaging showed bilateral ground-glass opacities, a pattern consistent with lipid-mediated injury rather than infectious pneumonia. Some patients required mechanical ventilation. Some died. The median age of hospitalized patients was 24, and the majority were male, demographics that reflected the user base of illicit THC cartridges rather than a biological susceptibility.

What the patients were using

The demographic and product-use data from the outbreak was specific. Among patients with available data, approximately 82% reported using THC-containing products, and many reported purchasing these products from informal sources: friends, family, dealers, or online marketplaces [4]. These were not regulated products from licensed dispensaries.

The vitamin E acetate was used as a cutting agent, a diluent that thickened the THC oil to give the appearance of higher quality or higher concentration. In illicit markets, where there is no testing and no labeling oversight, the incentive to cut expensive THC distillate with a cheap thickener is obvious. The buyer cannot distinguish a cut cartridge from a pure one by appearance, because the vitamin E acetate makes the oil look the same.

Nicotine-only products were reported by some patients, but the investigation consistently pointed to THC products as the primary driver. Vitamin E acetate was not found in regulated nicotine e-liquids. The compound has no function in nicotine formulations: nicotine e-liquids use propylene glycol and vegetable glycerin as carriers, which are water-soluble and do not produce lipid-mediated lung injury through the same mechanism. The self-reported nicotine-only use by some patients is a known limitation of case investigations. People are not always forthcoming about illicit drug use, particularly when they are being questioned in a hospital, and the stigma around THC use in states where it was not yet legal likely led to underreporting of THC cartridge use among the hospitalized patients.

What the outbreak did not show

EVALI did not show that nicotine vaping causes severe lung injury. The distinction matters, not because nicotine vaping is risk-free (it is not; the evidence on respiratory irritation and inflammatory markers is real and covered separately on this site), but because conflating the two undermines accurate risk assessment.

The public health messaging during the outbreak was sometimes imprecise on this point. “Vaping causes lung injury” appeared in many headlines without the qualifier “when using illicit THC products containing vitamin E acetate.” This created a risk communication problem that went in both directions: some nicotine vapers were scared into believing their product caused EVALI, while some smokers who had switched to nicotine vaping returned to cigarettes because they believed vaping was equally dangerous [5]. Neither response was supported by the evidence.

This matters for a site about quitting vaping, because readers arrive with varying levels of fear about what vaping has done to their lungs. If you used only standard nicotine vaping products from regulated sources, EVALI is not your risk. Your risks are the ones associated with chronic aerosol inhalation: respiratory irritation, potential cardiovascular effects, and nicotine dependence itself. These are real, and they are different from what EVALI was.

The broader lessons

Two things are true at the same time. First, EVALI was caused by a specific contaminant in a specific product category, and the risk to nicotine vapers using regulated products was and is low. Second, the outbreak demonstrated that the contents of what you inhale matter enormously, and that unregulated supply chains carry risks that regulated ones do not.

The lungs are not designed to process lipid aerosols. They are not designed to process the aerosol from nicotine e-liquids either, to be clear, but the scale of harm is different. EVALI caused acute, severe injury because the contaminant directly disabled the gas-exchange surface. The respiratory effects of standard nicotine vaping are subtler: chronic irritation, inflammatory changes in the airway epithelium, effects that accumulate over months and years rather than presenting as an emergency. Both are reasons to consider quitting. But they are different risks, with different mechanisms and different timelines, and treating them as one story helps no one.

For anyone still vaping, nicotine or otherwise: buy from regulated sources. Do not use cartridges or liquids from unlicensed sellers, friends, or online marketplaces. Do not modify devices or liquids. These are basic harm-reduction measures that the EVALI outbreak made urgently concrete.

Where we are now

EVALI cases dropped sharply once the cause was identified and public awareness increased. Sporadic cases continue to be reported, generally linked to unregulated products. The outbreak did prompt some regulatory responses, including increased scrutiny of THC vaping products in states with legal cannabis markets, and increased FDA focus on e-cigarette product standards. Several states implemented temporary or permanent bans on certain vaping products, though the bans were often broader than the evidence warranted, sometimes covering flavored nicotine products that had no connection to the EVALI cases. The regulatory response was a case study in how fear can produce policy that overshoots the evidence: the problem was illicit THC cartridges, and some of the responses targeted legal nicotine products instead.

The investigation itself is worth noting as an example of public health epidemiology working well under pressure. The cause was identified within months, the specific compound was isolated, the exposure pathway was established, and the case count declined as awareness spread. The gap between the investigation and the headlines, where precision was sometimes lost, is a separate problem, and a familiar one in any fast-moving health story.

The clinical presentation is also worth understanding for what it taught about acute lung injury from inhaled substances. EVALI patients presented with respiratory symptoms (cough, shortness of breath, chest pain), gastrointestinal symptoms (nausea, vomiting, diarrhea), and systemic signs (fever, fatigue, weight loss). Imaging typically showed bilateral ground-glass opacities, a pattern consistent with chemical pneumonitis or lipoid pneumonia. The severity ranged from mild illness requiring outpatient management to respiratory failure requiring mechanical ventilation. Some patients, particularly those with underlying health conditions or who presented late, died. The clinical picture was consistent with a chemical lung injury from an inhaled lipid-based substance, which is exactly what vitamin E acetate turned out to be: an oil-based compound that the lungs could not clear, triggering an inflammatory response that damaged the alveolar tissue.

For a site about quitting vaping, EVALI is relevant context rather than the central argument. The case for quitting nicotine vaping rests on the evidence about nicotine dependence and the respiratory and cardiovascular effects of chronic aerosol inhalation, not on a specific outbreak caused by a different product. Understanding what EVALI was, and what it was not, is part of reading the evidence clearly. The reader who quits vaping because of EVALI is quitting for the wrong reason, and the reader who dismisses all vaping risks because EVALI was misattributed is also reading the evidence incorrectly. Both positions improve when the facts are separated from the fear.

If you’d like support quitting, the Quitline (1-800-QUIT-NOW in the US) and smokefree.gov have free resources. Your doctor or pharmacist can also advise on NRT.